On August 14, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the second quarter of 2024 and provided a business update. The company recently completed enrollment in the single ascending dose (SAD) Part 1 portion of the Phase 1 trial of DA-1726 and we anticipate topline results in the third quarter of 2024. The multiple ascending dose (MAD) Part 2 portion of the Phase 1 trial is enrolling and topline results are expected in the first quarter of 2025. The planned Part 3 portion of the Phase 1 trial will assess weight loss at 24 weeks with an interim data readout expected in mid-2026 and topline data expected in the second half of 2026. The company recently completed a financing of up to $70 million with $20 million upfront and $50 million of clinical milestone-based warrants to potentially fund operations through Part 3 of the Phase 1 trial.
